Sign in Subscribe
Class action lawsuits

Novo Nordisk Class Action Lawsuit Filed for Securities Laws Violations

Strategic Insights

— 1 min read

A class action lawsuit has been filed against Novo Nordisk A/S, a Danish multinational pharmaceutical company, alleging violations of federal securities laws. The lawsuit, filed by Bronstein, Gewirtz & Grossman, LLC, seeks to recover damages for investors who purchased Novo Nordisk securities between May 7, 2025, and July 28, 2025. The complaint alleges that Novo Nordisk made false and misleading statements about its growth potential, misrepresented the likelihood of patients transitioning to branded alternatives, and overstated the GLP-1 market size and penetration.

Key Takeaways:

  • The lawsuit alleges that Novo Nordisk made false and misleading statements about its growth potential, specifically regarding its ability to penetrate the GLP-1 market.
  • The complaint alleges that the company misrepresented the likelihood of patients transitioning to branded alternatives, which affected its growth prospects.
  • The lawsuit claims that Novo Nordisk significantly overstated the size of the GLP-1 market and its ability to sustain growth in this market.
  • The class action lawsuit was filed on behalf of all persons and entities that purchased or acquired Novo Nordisk securities during the Class Period (May 7, 2025 - July 28, 2025).
  • Investors are encouraged to join the case by visiting the firm's website.
  • The lawsuit aims to recover damages for investors who suffered losses due to Novo Nordisk's alleged securities law violations.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

Statistics:

  • The lawsuit covers a period from May 7, 2025, to July 28, 2025 (Class Period).
  • The complaint alleges that Novo Nordisk securities were sold or acquired by investors during this period.
  • Investors have until September 30, 2025, to request the Court to appoint them as lead plaintiffs.
  • The firm represents investors on a contingency fee basis, meaning that attorneys' fees and out-of-pocket expenses will be reimbursed only if they are successful.

Sources:

  • Globe Newswire: "Novo Nordisk A/S (NYSE: NVO) Investor Alert: Lawsuit Filed" (September 01, 2025)
  • Bronstein, Gewirtz & Grossman, LLC: Attorney Advertising (September 01, 2025)

Read more